INBIOGEN CO.,Ltd Logo

INBIOGEN CO.,Ltd

A life sciences firm offering bioinformatics and data mining services to biotech firms.

101140 | KO

Overview

Corporate Details

ISIN(s):
KR7101140002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로135길 21 2층(논현동), 강남구

Description

INBIOGEN is a life sciences company that provides Virtual Biotech Assistance to international biotechnology companies, pharmaceutical firms, and research organizations. The company specializes in harnessing data mining to deliver a range of services, including bioinformatics, custom data curation, database development, and the creation of operational platforms. Core bioinformatics offerings encompass data analysis, protein modeling, homology searches, phylogeny, and immunogenicity analysis. Additionally, INBIOGEN provides virtual research, marketing assistance, and web development services. The company focuses on creating customized, value-added solutions through a team of experienced scientists and bioinformatics professionals to help clients address challenges and utilize online resources effectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-01-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2022-12-30 00:00
기타경영사항(자율공시)
Korean 14.0 KB
2022-12-30 00:00
최대주주등소유주식변동신고서
Korean 24.0 KB
2022-12-15 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 52.7 KB
2022-11-25 00:00
주식등의대량보유상황보고서(일반)
Korean 79.3 KB
2022-11-25 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2022-11-21 00:00
최대주주등소유주식변동신고서
Korean 23.2 KB
2022-11-18 00:00
유상증자또는주식관련사채등의발행결과(자율공시)
Korean 5.5 KB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 854.2 KB
2022-11-10 00:00
주요사항보고서(유상증자결정)
Korean 30.8 KB
2022-11-04 00:00
주식등의대량보유상황보고서(일반)
Korean 74.6 KB
2022-11-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.4 KB
2022-10-28 00:00
주식등의대량보유상황보고서(일반)
Korean 73.5 KB
2022-10-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2022-10-28 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 52.7 KB

Automate Your Workflow. Get a real-time feed of all INBIOGEN CO.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for INBIOGEN CO.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for INBIOGEN CO.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.